1 citations
,
February 2020 in “PubMed” This study found that a topical compounded formulation may improve hair density and general appearance in male patients with androgenetic alopecia after 6 months of use.
In this large retrospective study, patients using compounded topical finasteride and minoxidil through a telehealth platform for male androgenetic alopecia reported high satisfaction and low incidence of side effects, with no need for higher care or treatment discontinuation due to adverse reactions.
December 2025 in “JMIR Dermatology” This study observed that patients using a novel topical combination of finasteride and minoxidil for male androgenetic alopecia reported high satisfaction and good tolerance, with few side effects and no need for higher-level care, despite limitations such as retrospective data and no control group.
September 2024 in “Journal of the American Academy of Dermatology” This study found that a new compounded topical solution for alopecia was clinically tolerable and did not cause irritation, while also showing potential to enhance hair growth through fibroblast proliferation and gene expression.
In this study, researchers assessed the stability of various formulations in the TrichoConcept™ line for customized alopecia treatment. They found that the combinations remained stable from 14 to 180 days, supporting the use of these vehicles for enhancing therapeutic outcomes in hair loss treatments.